FibroBiologics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FibroBiologics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.65M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($11.16M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($16.49M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.12M) | Feb 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.65M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($13.74M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($8.89M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.47M) | Feb 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.41M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $2.37M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Feb 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.39M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($11.90M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($6.40M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($4.07M) | Feb 29, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $184.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $495.0K | Mar 31, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.62M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $16.45M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.82M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.82M | Feb 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.71M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $10.57M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.82M | Feb 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.16M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.74M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.25M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($4.00M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($1.29M) | Feb 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.16M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($35.52M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($24.36M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.87M) | Feb 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $13.99M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $9.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.27M | Feb 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |